Thompson Davis & CO. Inc. Makes New $181,000 Investment in Myomo, Inc. (NYSEAMERICAN:MYO)

Thompson Davis & CO. Inc. bought a new position in shares of Myomo, Inc. (NYSEAMERICAN:MYO) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 28,150 shares of the company’s stock, valued at approximately $181,000. Thompson Davis & CO. Inc. owned 0.09% of Myomo at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Barclays PLC acquired a new position in Myomo during the third quarter worth about $36,000. Jane Street Group LLC acquired a new stake in shares of Myomo in the third quarter valued at approximately $65,000. Calamos Advisors LLC acquired a new stake in shares of Myomo in the fourth quarter valued at approximately $189,000. XTX Topco Ltd acquired a new stake in shares of Myomo in the third quarter valued at approximately $149,000. Finally, Palumbo Wealth Management LLC acquired a new stake in shares of Myomo in the fourth quarter valued at approximately $242,000. 44.99% of the stock is currently owned by institutional investors and hedge funds.

Myomo Stock Performance

Shares of MYO opened at $5.74 on Friday. Myomo, Inc. has a 1 year low of $2.51 and a 1 year high of $7.17.

Analysts Set New Price Targets

Several analysts have recently commented on MYO shares. HC Wainwright reiterated a “buy” rating and issued a $7.50 price target on shares of Myomo in a research report on Wednesday, November 13th. Ascendiant Capital Markets increased their price target on shares of Myomo from $8.50 to $9.00 and gave the company a “buy” rating in a research report on Tuesday, November 12th. Finally, Craig Hallum increased their price target on shares of Myomo from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, December 13th.

Myomo Profile

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.